N2OFF, Inc. has announced an update to its ongoing acquisition of MitoCareX Bio Ltd. The company has amended the Securities Purchase and Exchange Agreement initially disclosed in February 2025. The amendment, dated May 18, 2025, extends the exclusivity period by an additional 90 days, allowing either party to terminate the agreement if the closing date does not occur within 180 days from the agreement's original date. This extension provides more time for N2OFF, Inc. to finalize the acquisition, which will result in MitoCareX becoming a wholly-owned subsidiary.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.